Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Griffin

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Journal of Leukocyte Biology|November 2, 2016
Editorial: A stake in the game: ADAM23 contributes to dendritic cell effectiveness in stimulating CD4+ T cell proliferative responsesJoana Cabral, Matthew D Griffin
The Journal of Steroid Biochemistry and Molecular Biology|July 20, 2005
Multiple potential clinical benefits for 1alpha,25-dihydroxyvitamin D3 analogs in kidney transplant recipientsMatthew D Griffin, Rajiv Kumar
Kidney International|April 20, 2020
Mesenchymal stromal cell-based therapies for acute kidney injury: progress in the last decadeBarbara Fazekas, Matthew D Griffin
Frontiers in Immunology|June 24, 2021
Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?Sarah Cormican, Matthew D Griffin
Journal of the American Society of Nephrology : JASN|March 16, 2013
The renal lymph node and immune tolerance to filtered antigensJana Pindjakova, Matthew D Griffin
Kidney International|November 27, 2008
First responders: understanding monocyte-lineage traffic in the acutely injured kidneySundararaman Swaminathan, Matthew D Griffin
Kidney International|August 16, 2011
Defective neutrophil rolling and transmigration in acute uremiaJana Pindjakova, Matthew D Griffin
Kidney International|April 1, 2014
Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factorSenthilkumar Alagesan, Matthew D Griffin
Frontiers in Pharmacology|March 3, 2020
Editorial: Innovative Biologics and Drugs to Target Renal InflammationMatthew D Griffin, Sundararaman Swaminathan
Pediatric Research|September 23, 2025
The CX3CR1/CX3CL1 (fractalkine) pathway in IgA vasculitis nephritis: guilty party or innocent bystander?Patricio E Ray, Matthew D Griffin
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Journal of Leukocyte Biology|November 2, 2016
Editorial: A stake in the game: ADAM23 contributes to dendritic cell effectiveness in stimulating CD4+ T cell proliferative responsesJoana Cabral, Matthew D Griffin
The Journal of Steroid Biochemistry and Molecular Biology|July 20, 2005
Multiple potential clinical benefits for 1alpha,25-dihydroxyvitamin D3 analogs in kidney transplant recipientsMatthew D Griffin, Rajiv Kumar
Kidney International|April 20, 2020
Mesenchymal stromal cell-based therapies for acute kidney injury: progress in the last decadeBarbara Fazekas, Matthew D Griffin
Frontiers in Immunology|June 24, 2021
Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?Sarah Cormican, Matthew D Griffin
Journal of the American Society of Nephrology : JASN|March 16, 2013
The renal lymph node and immune tolerance to filtered antigensJana Pindjakova, Matthew D Griffin
Kidney International|November 27, 2008
First responders: understanding monocyte-lineage traffic in the acutely injured kidneySundararaman Swaminathan, Matthew D Griffin
Kidney International|August 16, 2011
Defective neutrophil rolling and transmigration in acute uremiaJana Pindjakova, Matthew D Griffin
Kidney International|April 1, 2014
Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factorSenthilkumar Alagesan, Matthew D Griffin
Frontiers in Pharmacology|March 3, 2020
Editorial: Innovative Biologics and Drugs to Target Renal InflammationMatthew D Griffin, Sundararaman Swaminathan
Pediatric Research|September 23, 2025
The CX3CR1/CX3CL1 (fractalkine) pathway in IgA vasculitis nephritis: guilty party or innocent bystander?Patricio E Ray, Matthew D Griffin
Pageof 16